

1 **Impact of a National Immunisation Program on herpes zoster incidence in**  
2 **Australia**

3

4 *Running title:* Population impact of a zoster immunisation program

5

6 Jialing Lin <sup>a,\*</sup>, Timothy Dobbins <sup>a</sup>, James G Wood <sup>a</sup>, Carla Bernardo <sup>b</sup>, Nigel P Stocks  
7 <sup>b</sup>, Bette Liu <sup>a</sup>

8

9 <sup>a</sup> *School of Population Health, University of New South Wales, Sydney, NSW 2052,*  
10 *Australia.*

11 <sup>b</sup> *Discipline of General Practice, Adelaide Medical School, University of Adelaide,*  
12 *Adelaide, SA 5005, Australia.*

13

14 \* Corresponding author.

15 *E-mail address:* [jialing.lin@student.unsw.edu.au](mailto:jialing.lin@student.unsw.edu.au) (J. Lin), [t.dobbins@unsw.edu.au](mailto:t.dobbins@unsw.edu.au) (T.  
16 Dobbins), [james.wood@unsw.edu.au](mailto:james.wood@unsw.edu.au) (J. Wood), [carla.bernardo@adelaide.edu.au](mailto:carla.bernardo@adelaide.edu.au) (C.  
17 Bernardo), [nigel.stocks@adelaide.edu.au](mailto:nigel.stocks@adelaide.edu.au) (N.P. Stock), [bette.liu@unsw.edu.au](mailto:bette.liu@unsw.edu.au) (B.  
18 Liu).

19 **Summary**

20 *Objectives:* To evaluate the impact of the National Herpes Zoster (zoster)

21 Immunisation Program in Australia on zoster incidence.

22 *Methods:* Ecological analysis of zoster incidence related to timing of implementation  
23 of the national program in vaccine-targeted (70-79 years) and non-targeted age groups  
24 (60-69 and 80-89 years) during January 2013-December 2018 was estimated using  
25 interrupted time-series analyses.

26 *Results:* Prior to program commencement (Jan 2013 to Oct 2016) in patients aged  
27 60-69, 70-79 and 80-89 years, incidence was mostly stable averaging respectively 7.2,  
28 9.6 and 10.8 per 1000 person-years. In the two years following program  
29 commencement, incidence fell steadily in those aged 70-79 years, with an estimated  
30 decrease of 2.25 (95% CI: 1.34, 3.17) per 1000 person-years per year, with women  
31 having a greater decrease than men (2.83 versus 1.68, p-interaction<0.01). In the two  
32 non-vaccine-program-targeted age groups there was no evidence of reduction in  
33 zoster incidence: 60-69 years, 0.46 (95% CI: -0.46, 1.38) and 80-89 years, 0.11 (95%  
34 CI: -1.64, 1.87).

35 *Conclusions:* Two years after implementation, an estimated 7000 zoster cases were  
36 prevented through the national program. With known waning vaccine efficacy,  
37 continued surveillance is needed to ensure these early reductions in incidence are  
38 sustained.

39

40 *Keywords:* Immunisation, herpes zoster, general practitioner, electronic medical  
41 records

## 42 **Introduction**

43 Herpes zoster (zoster) is a painful rash that occurs following reactivation of the  
44 varicella zoster virus. It is more frequently observed in older people and those who  
45 are immunocompromised.<sup>1</sup> It can cause prolonged and severe pain leading to  
46 significant health problems including difficulty mobilising and also psychological  
47 conditions, such as anxiety, depression, and even social isolation.<sup>2</sup> The lifetime risk of  
48 acquiring zoster is 20-30%, with incidence increasing with age.<sup>3, 4</sup> A recent study  
49 reported annual age-specific zoster incidence of 1.8 per 1000 persons for those aged  
50 under 25 years, 6.3 per 1000 for 50-59 year olds, and 19.9 per 1000 for those aged 80  
51 years and over in Australia.<sup>5</sup>

52 Two effective zoster vaccines are currently registered; one is a live-attenuated  
53 vaccine with reported one-dose efficacy of 51.3% against zoster in adults aged 60  
54 years and over<sup>6</sup> and the other, a recombinant subunit adjuvanted vaccine with  
55 two-dose efficacy of 97.2% against zoster in adults aged 50 years and over<sup>7</sup>. In  
56 Australia, the live-attenuated vaccine was registered in 2007 but not available until  
57 2013 by private prescription. The recombinant subunit adjuvanted vaccine was  
58 registered in 2018 but is not available yet. Since November 2016 in Australia under a  
59 National Herpes Zoster Immunisation Program, a single dose of the live-attenuated  
60 zoster vaccine has been offered to adults aged 70 years with a time-limited catch-up  
61 program for those aged 71-79 years until 2021.<sup>8</sup> Evaluating the impact of this national  
62 program on zoster incidence has been limited by the fact that in Australia zoster is not  
63 notifiable in all states and territories,<sup>9</sup> and the reliability of reporting of zoster to public  
64 health units is uncertain with notifications likely to underestimate true rates. Also,  
65 internationally there is only one other impact evaluation of a national zoster program.<sup>10</sup>

66 Therefore, in order to add to the limited knowledge regarding zoster vaccine  
67 program effects at a population level, the aim of this study was to evaluate the impact  
68 of the National Herpes Zoster Immunisation Program on zoster incidence by using a  
69 large national general practice dataset.

70

## 71 **Methods**

72 *Ethics*

73 This study was approved by the MedicineInsight Independent External Data  
74 Governance Committee (reference number 2018-015) and the University of New  
75 South Wales Human Research Ethics Committee (No. HC180939).

76

#### 77 *Data source*

78 MedicineInsight is a large, longitudinal general practice dataset with data extracted  
79 from electronic medical records in general practices across Australia. Participating  
80 general practices consent to provide de-identified data on an ongoing basis to the  
81 MedicineInsight program. The program was developed and is managed by NPS  
82 MedicineWise. The dataset contains separate tables with patient demographic records,  
83 diagnoses, reasons for encounter, and prescriptions made during patient encounters.  
84 Each record is dated and is assigned a unique patient identifier. This enables records  
85 related to the same individual to be linked. More details of this dataset are available  
86 elsewhere.<sup>11, 12</sup> In this study, we used an extract containing records from 25% of  
87 patients randomly selected from the whole dataset with complete records to 31<sup>st</sup>  
88 December 2018.

89

#### 90 *Study population*

91 For this analysis we used presentations recorded in the MedicineInsight dataset  
92 from 1<sup>st</sup> January 2013- 31<sup>st</sup> December 2018 in adults turning 60-89 years old. As  
93 people in Australia have unrestricted choice when accessing general practice services,  
94 we needed to define a regular attender for a population denominator to estimate  
95 incidence. As done previously<sup>13</sup>, we defined our main study population as those who  
96 had records of attending the same practice on at least one non-administrative visit  
97 each year in the previous two years. Administrative visits were those that only  
98 involved administrative notes, emails, faxes, file reviews, phone calls, and phone  
99 messages. In addition, patients recorded as deceased in that year, or with missing data  
100 on year of birth, sex or zoster diagnosis date were excluded from the study population.

101

102 *Definition of herpes zoster cases*

103 For our main analyses we defined a case as having a diagnosis of zoster if they had  
104 a term indicating zoster (zoster, HZ, shingles, zona) in either the encounter reason or  
105 diagnosis tables but not one of the exclusion terms. Exclusion terms included a word  
106 indicating only a possible/suspected diagnosis, or a term indicating the encounter was  
107 for vaccination, advice only, or related to a family member (see Appendix Table 1 for  
108 full list). Encounters where there was a record of a zoster vaccine administered in the  
109 immunisation table on the same date were also excluded as cases. As both the  
110 encounter reason and diagnosis tables were free text, to include possible misspellings,  
111 we used the SPEDIS function with cost  $\leq 30$  in SAS to identify closely related  
112 spellings to our zoster terms.

113

114 *Data analysis*

115 All records that met the case definition with the same patient identifier and record  
116 date were considered duplicates and removed before data analysis. If participants had  
117 more than one record of a zoster diagnosis over the study period, records that were  
118 separated by more than 180 days during the observation period were considered as  
119 distinct episodes of zoster<sup>14</sup> and contributed to counts of events. For each calendar  
120 year of data, we divided participants into three groups based on the age they turned in  
121 that year: 60-69, 70-79 (targeted for vaccination), and 80-89 years old. Zoster  
122 incidence in each month and the year of observation was estimated by calculating the  
123 number of zoster episodes recorded in that period divided by person-years of the  
124 study population meeting the regular attender definition in that year.

125 For estimating annual zoster incidence before and after the national program, we  
126 separated data into the three-year time period from November 2013 to October 2016  
127 which was considered “before the program”, and the two-year period from November  
128 2016 to October 2018 which was considered “after the program”. We estimated zoster  
129 incidence in each period (before and after the program) and the relative and absolute  
130 reductions in incidence comparing the periods, stratified by age and sex. We also

131 calculated incidence before and after the program in those 70-79 years by practice  
132 jurisdiction, remoteness status<sup>15</sup> and area-level socioeconomic disadvantage using the  
133 index of relative socioeconomic advantage and disadvantage (IRSAD)<sup>16</sup>.

134 We used an interrupted time-series model<sup>17</sup> to further investigate the effect of the  
135 national program on zoster incidence. We defined January 2013-October 2016 as the  
136 pre-program period and November 2016-December 2018 as the post-program period.  
137 A segmented regression was used, including terms to estimate the base level of  
138 incidence at the beginning of the series, the pre-program trend in incidence, the  
139 change in level of incidence immediately after the program and the change in trend of  
140 incidence after the program. We assessed serial autocorrelation graphically and via  
141 the Durbin-Watson statistic, accounting for autocorrelation where necessary by  
142 including an auto-regressive term. Model assumptions were checked using graphical  
143 summaries of residuals. In addition, we calculated the total number of zoster cases  
144 averted in the vaccine-targeted age group in Australia by applying our estimates of  
145 absolute reduction to population estimates from the 2016 census.<sup>18</sup>

146 All analyses were conducted with SAS v. 9.4 (SAS Institute Inc. Cary, North  
147 Carolina, USA).

148

#### 149 *Sensitivity analysis*

150 In the first sensitivity analysis we re-defined the study population, to be consistent  
151 with the Royal Australian College of General Practitioners (RACGP)<sup>19</sup> which defines  
152 a regular attender as a patient who attended the same practice for at least three  
153 non-administrative visits on different days within the last two years. For the second,  
154 we broadened the definition of a zoster case by including those with a prescription  
155 record of a zoster-specific antiviral (see Appendix Table 2 for details). This included  
156 acyclovir (800 mg) with 35 tablets, valacyclovir (500 mg) with 42 tablets, or  
157 famciclovir (250 mg) with 21 tablets.<sup>20</sup>

158

## 159 **Results**

160 For each analysis year, there were: between 50814 and 62677 regular attenders  
161 aged 70-79 years, 82248 to 89542 aged 60-69 years, and 27166 to 29866 aged 80-89  
162 years. For the vaccine-targeted age group (70-79 years), there were 2439 patients who  
163 met the zoster case definition over the five-year period, Nov 2013-Oct 2018. For the  
164 two non-vaccine-targeted age groups, 60-69 and 80-89 years of age, the  
165 corresponding figures were 1495 and 550, respectively.

166 Table 1 shows the crude average annual incidence of zoster before and after  
167 program commencement. Zoster incidence per 1000 person-years before and after the  
168 program was 9.5 versus 7.5 for those 70-79 years, 7.7 versus 8.3 for those 60-69 years  
169 and 9.0 versus 9.3 for those 80-89 years. Among those aged 70-79 years the absolute  
170 reduction in incidence was 2.0 per 1000 person-years or a relative reduction of 21%.  
171 Such falls were not observed in either the 60-69 or the 80-89 years age groups.  
172 Women had consistently higher incidence than men in all age groups both before and  
173 after program commencement and falls in incidence were observed for both men and  
174 women aged 70-79 years. Among the vaccine-targeted population (aged 70-79 years)  
175 we also found incidence decreased after the program in all remoteness and  
176 socioeconomic status categories, and in most jurisdictions, except the Northern  
177 Territory and Western Australia (Appendix Table 3).

178 Trends in zoster incidence pre- and post- program by age group are shown in  
179 Figure 1. Prior to program commencement in patients aged 60-69, 70-79 and 80-89  
180 years, incidence was mostly stable averaging respectively 7.2, 9.6 and 10.8 per 1000  
181 person-years. However, following the program commencement, the incidence fell  
182 steadily in those aged 70-79 years.

183 From the interrupted time-series analysis, the trend in zoster incidence in the  
184 vaccine-targeted age group decreased by 2.25 (95% CI: 1.34, 3.17) per 1000  
185 person-years per year (Table 2). Women had a greater decrease than men (2.83 versus  
186 1.68, test for interaction <0.01). By contrast, there was no evidence of reductions in  
187 zoster incidence trends for the two non-vaccine-targeted age groups.

188

189 *Sensitivity analyses*

190 Use of the RACGP definition of a regular attender did not change the patterns in  
191 incidence. In those aged 70-79 years the post-program decrease in incidence was 1.98  
192 (95% CI: 1.13, 2.84) per 1000 person-years per year whilst there was no change in  
193 those 60-69 and those 80-89 years (see Appendix Table 4).

194 Using the broader zoster case definition resulted in higher incidences but the  
195 patterns were similar. Before and after the program for those aged 60-69, 70-79,  
196 80-89 years respectively: 9.4 versus 10.0, 11.5 versus 9.1, 11.0 versus 11.2 per 1000  
197 person-years. There was also evidence of a reduction in incidence trends in the 70-79  
198 years age group (reduction: 2.45 (95% CI: 1.63, 3.27) per 1000 person-years per year)  
199 but not in either the 60-69 or the 80-89 years age groups (see Appendix Table 5).

200

201 **Discussion**

202 To the best of our knowledge, this is the first study to estimate the impact of the  
203 National Zoster Immunisation Program on zoster incidence in Australia. We found  
204 that in the two years after implementation, zoster incidence decreased by 2.25 per  
205 1000 person-years per year or by about 40% from pre-program levels in the  
206 vaccine-targeted population (those aged 70-79 years); no significant falls were  
207 recorded in those aged 60-69 and 80-89 years.

208 Our findings are consistent with studies in other countries and regions that have  
209 also implemented and evaluated zoster immunisation programs with live-attenuated  
210 zoster vaccines. England introduced a zoster immunisation program for 70 year olds  
211 with phased catch-up for those 71-79 years in September 2013.<sup>10</sup> After three years,  
212 vaccine coverage was reported as 60% in the vaccine-targeted population, and zoster  
213 incidence was reported to decrease by 3.1 per 1000 person-years. In the Canadian  
214 province of Ontario, a zoster immunisation program was introduced in September  
215 2016 for adults aged 65-70 years.<sup>21</sup> Results of a national survey showed vaccine  
216 uptake was 21% among participants aged  $\geq 50$  years in 2016<sup>22</sup> and the monthly



217 incidence of medically-attended zoster in the 2 years after program implementation  
218 was reported to decrease by 1 per 10,000 population<sup>21</sup>.

219 Some of the differences in the estimated impact of the zoster immunisation  
220 program in Australia compared to other regions could be due to differences in zoster  
221 case ascertainment used in this study and vaccine coverage achieved. Estimates of  
222 zoster vaccine uptake in Australia are limited. A report based on data from the  
223 Australian Immunisation Register suggested that cumulative vaccine coverage 23  
224 months after program commencement in Australia was 31.2% among adults aged  
225 70-79 years but this is considered an underestimate due to underreporting.<sup>23</sup> Using  
226 this same general practice database (MedicineInsight) in a separate study we have  
227 estimated higher coverage (47%) in the targeted population 2 years after program  
228 commencement.<sup>13</sup>

229 Women had both higher incidence of zoster but also greater reductions in incidence  
230 than men following program implementation, and this might be explained by higher  
231 vaccine uptake in women than men.<sup>13, 23</sup> This sex difference was also observed in the  
232 Canadian study.<sup>21</sup> The fall in incidence post-program was also observed to be  
233 relatively uniform across Australian regions (by remoteness) and socioeconomic  
234 groups, and also in most jurisdictions, although not in the Northern Territory and  
235 Western Australia. The lack of a reduction in incidence in the Northern Territory may  
236 be due to the small number of participating practices in our sample and therefore a  
237 lack of power to detect a difference; although vaccine coverage in the Northern  
238 Territory is also reported to be substantially lower<sup>23</sup>. The lack of change in incidence  
239 detected in Western Australia is more difficult to explain as coverage is reportedly  
240 similar to other jurisdictions<sup>23</sup> and further investigation is required to confirm this  
241 difference.

242 Study strengths include the use of a large national general practice dataset of  
243 electronic medical records allowing us sufficient numbers of cases in age groups to  
244 investigate changes over time. However, there are some limitations. Firstly, we only  
245 studied people attending GPs so zoster cases diagnosed in settings such as emergency

246 departments or hospitals or at GPs not participating in the MedicineInsight database  
247 would be missed but this proportion is likely to be small and unlikely to differ  
248 between the pre- and post-program periods examined. Secondly, there is the potential  
249 for misclassification of zoster cases and we were unable to validate the case records.  
250 However, we used the same case definition consistently over time and in different age  
251 groups and we included a range of terms and misspellings to improve detection and  
252 exclude questionable cases. The fact we observed a fall in incidence coinciding with  
253 the time of program implementation and only in vaccine-targeted age groups suggest  
254 that our definition was valid.

255

## 256 **Conclusion**

257 In summary, our study shows that the recently implemented National Herpes Zoster  
258 Immunisation Program in Australia has had a significant impact on reducing zoster  
259 incidence among the vaccine-targeted population and that the level of reduction  
260 appears to be consistent with other regions in the world that have similar programs in  
261 place, given differences in vaccine uptake. Based on Australian census data<sup>24</sup> for the  
262 population aged 70-79 years (N=1,540,376), we estimate about 7000 zoster cases  
263 would have been averted two years after the program commenced. Given the known  
264 waning of vaccine efficacy for the live-attenuated vaccine,<sup>25</sup> longer-term evaluation of  
265 this program is also needed to ensure that zoster incidence continues to decrease.

266

## 267 **Acknowledgements**

268 We thank the NPS MedicineWise MedicineInsight for providing the data for this  
269 study. J. Lin is supported by the University International Postgraduate Awards under a  
270 UNSW Tuition Fee Scholarship and a School of Population Health Stipend  
271 Scholarship. B. Liu is supported by an NHMRC Fellowship.

272

## 273 **Declaration of Competing Interest**

274 None.

275 **References**

- 276 1. Arvin AM. Varicella-zoster virus. *Clin Microbiol Rev* 1996;**9**(3):361.
- 277 2. Lang P-O, Aspinall R. Vaccination in the Elderly: What Can Be Recommended? *Drugs*  
278 *& Aging* 2014;**31**(8):581-99.
- 279 3. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?  
280 *Lancet Infect Dis* 2004;**4**(1):26-33.
- 281 4. Schmader K. Herpes zoster in older adults. *Clin Infect Dis* 2001;**32**(10):1481-6.
- 282 5. MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A. Increasing  
283 trends of herpes zoster in Australia. *PLoS ONE* 2015;**10**(4):e0125025.
- 284 6. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A  
285 Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. *N Engl J*  
286 *Med* 2005;**352**(22):2271-84.
- 287 7. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al.  
288 Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. *N Engl J*  
289 *Med* 2015;**372**(22):2087-96.
- 290 8. Australian Government Department of Health. National Immunisation Program Schedule.  
291 2017 [cited 2020 5 June]. Available from:  
292 [https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/nati](https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule)  
293 [onal-immunisation-program-schedule](https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule).
- 294 9. Sheel M, Beard I F, Quinn II H, Dey A, Kirk M, Koehler A, et al. Australian vaccine  
295 preventable disease epidemiological review series: varicella-zoster virus infections,  
296 1998–2015. *J Commun Dis Intell* 2016;**40**(1):E189-E93.
- 297 10. Amirthalingam G, Andrews N, Keel P, Mullett D, Correa A, de Lusignan S, et al.  
298 Evaluation of the effect of the herpes zoster vaccination programme 3 years after its  
299 introduction in England: a population-based study. *Lancet Public Health*  
300 2018;**3**(2):e82-e90.
- 301 11. NPS MedicineWise. MedicineInsight Data Book version 2.2. June 2019 [cited 2020 5  
302 June]. Available from:  
303 [https://www.nps.org.au/assets/NPS/pdf/MedicineInsight\\_databook\\_June-2019.pdf](https://www.nps.org.au/assets/NPS/pdf/MedicineInsight_databook_June-2019.pdf).
- 304 12. Busingye D, Gianacas C, Pollack A, Chidwick K, Merrifield A, Norman S, et al. Data  
305 Resource Profile: MedicineInsight, an Australian national primary health care database.  
306 *Int J Epidemiol* 2019;**48**(6):1741–h.
- 307 13. Lin J, Wood JG, Bernardo C, Stocks NP, Liu B. Herpes zoster vaccine coverage in  
308 Australia before and after introduction of a national vaccination program. *Vaccine*  
309 2020;**38**(20):3646-52.
- 310 14. Donahue JG, Choo PW, Manson JE, Platt R. The Incidence of Herpes Zoster. *Arch*  
311 *Intern Med* 1995;**155**(15):1605-9.
- 312 15. Australian Bureau of Statistics. Australian Statistical Geography Standard (ASGS). 2018  
313 [cited 2020 5 June]. Available from:  
314 <https://www.abs.gov.au/websitedbs/D3310114.nsf/home/Australian+Statistical+Geograp>  
315 [hy+Standard+\(ASGS\)](https://www.abs.gov.au/websitedbs/D3310114.nsf/home/Australian+Statistical+Geograp).
- 316 16. Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA) 2016. March  
317 2018 [cited 2020 5 June]. Available from:

- 318 <https://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/756EE3DBEFA869EFCA258>  
319 [259000BA746/\\$File/SEIFA%202016%20Technical%20Paper.pdf](https://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/756EE3DBEFA869EFCA258259000BA746/$File/SEIFA%202016%20Technical%20Paper.pdf).
- 320 17. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of  
321 interrupted time series studies in medication use research. *J Clin Pharm Ther*  
322 2002;**27**(4):299-309.
- 323 18. Australian Bureau of Statistics. 2016 Census. 2017 [cited 2020 5 June]. Available from:  
324 [https://www.abs.gov.au/websitedbs/D3310114.nsf/Home/Assuring%20Census%20Data](https://www.abs.gov.au/websitedbs/D3310114.nsf/Home/Assuring%20Census%20Data%20Quality)  
325 [%20Quality](https://www.abs.gov.au/websitedbs/D3310114.nsf/Home/Assuring%20Census%20Data%20Quality).
- 326 19. The Royal Australian College of General Practitioners. Standards for general practices  
327 (4th edition). 2015 [cited 2020 5 June]. Available from:  
328 <https://www.racgp.org.au/download/documents/Standards/standards4thedition.pdf>.
- 329 20. Liu B, Heywood AE, Reekie J, Banks E, Kaldor JM, McIntyre P, et al. Risk factors for  
330 herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study.  
331 *Epidemiol Infect* 2015;**143**(13):2871-81.
- 332 21. Martins D, McCormack D, Tadrous M, Gomes T, Kwong JC, Mamdani MM, et al.  
333 Impact of a publicly funded herpes zoster immunization program on the burden of  
334 disease in Ontario, Canada: a population-based study. [published online ahead of print,  
335 2020 Jan 10]. *Clin Infect Dis* 2020:ciaa014. doi: 10.1093/cid/ciaa014.
- 336 22. Public Health Agency of Canada. Vaccine uptake in Canadian adults : results from the  
337 2016 Adult National Immunization Coverage Survey (aNICS). 2018 [cited 2020 5 June].  
338 Available from:  
339 [http://publications.gc.ca/collections/collection\\_2018/aspc-phac/HP40-222-2018-eng.pdf](http://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-222-2018-eng.pdf).
- 340 23. National Centre for Immunisation Research and Surveillance. Exploratory analysis of the  
341 first 2 years of adult vaccination data recorded on AIR. 2019 [cited 2020 5 June].  
342 Available from:  
343 [http://ncirs.org.au/sites/default/files/2019-12/Analysis%20of%20adult%20vaccination%](http://ncirs.org.au/sites/default/files/2019-12/Analysis%20of%20adult%20vaccination%20data%20on%20AIR_Nov%202019.pdf)  
344 [20data%20on%20AIR\\_Nov%202019.pdf](http://ncirs.org.au/sites/default/files/2019-12/Analysis%20of%20adult%20vaccination%20data%20on%20AIR_Nov%202019.pdf).
- 345 24. Australian Bureau of Statistics. Patient Experiences in Australia: Summary of Findings,  
346 2017-18. 2018 [cited 2020 5 June]. Available from:  
347 [https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4839.02017-18?OpenDocum](https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4839.02017-18?OpenDocument)  
348 [ent](https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4839.02017-18?OpenDocument).
- 349 25. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al.  
350 Long-term persistence of zoster vaccine efficacy. *Clin Infect Dis* 2015;**60**(6):900-9.

351

352 **Table 1** Crude annual incidence of herpes zoster per 1000 person-years before and  
 353 after implementation of the National Herpes Zoster Immunisation Program among  
 354 patients attending General Practices in Australia, by age and sex.

Age, sex	Before program (Nov 2013-Oct 2016)	After program (Nov 2016-Oct 2018)
<b>60-69 y</b>		
Overall	7.7 (1979/256157)	8.3 (1495/179146)
Men	6.3 (753/119315)	6.6 (547/82576)
Women	9.0 (1226/136842)	9.8 (948/96570)
<b>70-79 y</b>		
Overall	9.5 (1518/160727)	7.5 (921/122779)
Men	8.4 (626/74847)	6.6 (381/57692)
Women	10.4 (892/85880)	8.3 (540/65087)
<b>80-89 y</b>		
Overall	9.0 (756/83874)	9.3 (550/59234)
Men	7.7 (272/35392)	8.9 (224/25130)
Women	10.0 (484/48482)	9.6 (326/34104)

355 Incidence is shown by the incidence rate (total number of zoster episodes/total number of  
 356 person-years).

357 **Table 2** Impact of the National Herpes Zoster Immunisation Program on trends in  
 358 incidence of herpes zoster among patients attending General Practices in Australia, by  
 359 age and sex.

Age, sex	Pre-program trend <sup>a</sup>	Post-program trend <sup>b</sup>	Change in trend	
			Estimate (95% CI)	<i>P</i> -value
<b>60-69 y</b>				
Overall	0.18 (-0.23, 0.59)	-0.28 (-1.05, 0.50)	-0.46 (-1.38, 0.46)	0.3
Men	-0.08 (-0.45, 0.29)	-0.20 (-1.17, 0.78)	-0.12 (-1.13, 0.88)	0.8
Women	0.22 (-0.35, 0.80)	-0.59 (-1.78, 0.61)	-0.81 (-2.19, 0.57)	0.3
<b>70-79 y</b>				
Overall	0.09 (-0.31, 0.48)	-2.16 (-2.94, -1.40)	-2.25 (-3.17, -1.34)	<0.001
Men	-0.09 (-0.53, 0.35)	-1.77 (-2.93, -0.62)	-1.68 (-2.87, -0.49)	<0.001
Women	0.06 (-0.50, 0.62)	-2.77 (-4.09, -1.45)	-2.83 (-4.26, -1.40)	<0.001
<b>80-89 y</b>				
Overall	-0.13 (-0.89, 0.62)	-0.25 (-1.75, 1.26)	-0.11 (-1.87, 1.64)	0.9
Men	-0.27 (-1.20, 0.66)	-0.16 (-2.12, 1.82)	0.11 (-2.12, 2.35)	0.9
Women	-0.08 (-1.04, 0.89)	-0.67 (-2.93, 1.60)	-0.59 (-3.05, 1.87)	0.6

360 CI, incidence interval.

361 <sup>a</sup>Pre-program trend (per 1000 person-years per year) is calculated over Jan 2013-Oct 2016  
 362 and shown by estimate (95% CI).

363 <sup>b</sup>Post-program trend (per 1000 person-years per year) is calculated over Nov 2016- Dec 2018  
 364 and shown by estimate (95% CI).

365 **Figure legend**

366 **Fig. 1.** Monthly incidence of herpes zoster per 1000 person-years among patients aged

367 (A) 60-69, (B) 70-79 and (C) 80-89 years old attending General Practices during Jan

368 2013-Dec 2018 in Australia.

